Recce Pharmaceuticals Ltd Net Assets

Latest as of June 2026: AU$-16.72 Million AUD ≈ $-11.83 Million USD

Recce Pharmaceuticals Ltd net assets. Based on the latest financial reports, Recce Pharmaceuticals Ltd (RCE) has net assets worth AU$-16.72 Million AUD (≈ $-11.83 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$8.53 Million ≈ $6.03 Million USD) and total liabilities (AU$25.25 Million ≈ $17.87 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Recce Pharmaceuticals Ltd annual equity growth to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$-16.72 Million
% of Total Assets	-196.09%
Annual Growth Rate	N/A
5-Year Change	-266.21%
10-Year Change	-2933.68%
Growth Volatility	305.09

Net Assets of Recce Pharmaceuticals Ltd (2013–2026)

Net assets of Recce Pharmaceuticals Ltd from 2013 to 2026. This chart illustrates how Recce Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. See RCE equity financing ratio to measure how much of total assets are equity-financed.

Annual Net Assets for Recce Pharmaceuticals Ltd (2013–2026)

The table below shows the annual net assets of Recce Pharmaceuticals Ltd from 2013 to 2026. For live market cap and overall valuation, see Recce Pharmaceuticals Ltd market capitalisation.

Year	Net Assets	Change
2026-06-30	AU$-16.72 Million ≈ $-11.83 Million	-447.93%
2025-06-30	AU$-3.05 Million ≈ $-2.16 Million	+67.95%
2024-06-30	AU$-9.52 Million ≈ $-6.74 Million	-267.88%
2023-06-30	AU$-2.59 Million ≈ $-1.83 Million	-125.73%
2022-06-30	AU$10.06 Million ≈ $7.12 Million	-50.93%
2021-06-30	AU$20.50 Million ≈ $14.51 Million	+786.62%
2020-06-30	AU$2.31 Million ≈ $1.64 Million	+670.16%
2019-06-30	AU$-405.60K ≈ $-286.99K	-158.37%
2018-06-30	AU$694.91K ≈ $491.70K	+17.75%
2017-06-30	AU$590.14K ≈ $417.56K	-83.21%
2016-06-30	AU$3.51 Million ≈ $2.49 Million	-25.46%
2015-06-30	AU$4.71 Million ≈ $3.34 Million	+8557.93%
2014-06-30	AU$-55.74K ≈ $-39.44K	+25.62%
2013-06-30	AU$-74.93K ≈ $-53.02K	--

Equity Component Analysis

This analysis shows how different components contribute to Recce Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 10132013500.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Recce Pharmaceuticals Ltd Net Assets Breakdown (June 2026)

Recce Pharmaceuticals Ltd net assets breakdown by equity component as of June 2026.

Component	Amount	Percentage
Common Stock	AU$81.73 Million	%
Other Comprehensive Income	AU$2.87 Million	%
Total Equity	AU$-16.72 Million	100.00%

Recce Pharmaceuticals Ltd Competitors by Market Cap

The table below lists competitors of Recce Pharmaceuticals Ltd ranked by their market capitalization.

Company	Market Cap
Ahn-Gook Pharmaceutical Co. Ltd KQ:001540	$71.40 Million
NWF GROUP PLC LS-25 F:NYY	$71.42 Million
AFC Gamma Inc NASDAQ:AFCG	$71.46 Million
Soosan Heavy I KO:017550	$71.47 Million
IBU tec advanced materials AG XETRA:IBU	$71.36 Million
Real Estate & E-Commerce Split Corp TO:RS	$71.32 Million
Kukdong Oil & KO:014530	$71.30 Million
Tasco Bhd KLSE:5140	$71.30 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Recce Pharmaceuticals Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2025 to 2026, total equity changed from -3,052,004 to -16,722,777, a change of -13,670,773.
Net loss of 14,961,430 reduced equity.
New share issuances of 3,940,000 increased equity.
Other comprehensive income decreased equity by 4,079,180.
Other factors increased equity by 1,429,837.

Equity Change Factors (2025 to 2026)

Factor	Impact	Contribution
Net Income	AU$-14.96 Million	-89.47%
Share Issuances	AU$3.94 Million	+23.56%
Other Comprehensive Income	AU$-4.08 Million	-24.39%
Other Changes	AU$1.43 Million	+8.55%
Total Change	AU$-	%

Book Value vs Market Value Analysis

This analysis compares Recce Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2013-06-30	AU$0.00	AU$0.33	x
2014-06-30	AU$0.00	AU$0.33	x
2015-06-30	AU$0.14	AU$0.33	x
2016-06-30	AU$0.06	AU$0.33	x
2017-06-30	AU$0.01	AU$0.33	x
2018-06-30	AU$0.01	AU$0.33	x
2019-06-30	AU$0.00	AU$0.33	x
2020-06-30	AU$0.02	AU$0.33	x
2021-06-30	AU$0.13	AU$0.33	x
2022-06-30	AU$0.06	AU$0.33	x
2023-06-30	AU$-0.01	AU$0.33	x
2024-06-30	AU$-0.05	AU$0.33	x
2025-06-30	AU$-0.01	AU$0.33	x
2026-06-30	AU$-0.06	AU$0.33	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Recce Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-90.19%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	0.00%	-75571.06%	0.00x	0.00x	AU$-284.94K
2014	0.00%	-280.43%	0.66x	0.00x	AU$-266.80K
2015	-9.55%	-395.39%	0.02x	1.06x	AU$-921.58K
2016	-137.75%	-2734.36%	0.05x	1.06x	AU$-5.19 Million
2017	-512.67%	-2172.01%	0.10x	2.48x	AU$-3.08 Million
2018	-240.93%	-129.94%	1.13x	1.65x	AU$-1.74 Million
2019	0.00%	-410.40%	0.74x	0.00x	AU$-2.75 Million
2020	-186.66%	-384.83%	0.35x	1.40x	AU$-4.55 Million
2021	-65.91%	-825.30%	0.08x	1.06x	AU$-15.56 Million
2022	-109.19%	-356.12%	0.24x	1.25x	AU$-11.99 Million
2023	0.00%	-299.58%	1.71x	0.00x	AU$-12.82 Million
2024	0.00%	-351.24%	0.79x	0.00x	AU$-16.71 Million
2025	0.00%	-285.37%	0.60x	0.00x	AU$-21.12 Million
2026	0.00%	0.00%	0.00x	0.00x	AU$-13.29 Million

Industry Comparison

This section compares Recce Pharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $5,978,783
Average return on equity (ROE) among peers: -142.18%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Recce Pharmaceuticals Ltd (RCE)	AU$-16.72 Million	0.00%	N/A	$71.40 Million
Adalta Ltd (1AD)	$5.38 Million	-112.69%	0.98x	$5.41 Million
Algorae Pharmaceuticals Ltd (1AI)	$5.13 Million	-137.38%	0.07x	$12.88 Million
ACRUX Ltd (ACR)	$9.09 Million	-108.18%	0.68x	$2.61 Million
Actinogen Medical Ltd (ACW)	$15.36 Million	-35.37%	0.01x	$92.21 Million
Argenica Therapeutics Ltd (AGN)	$8.31 Million	-49.24%	0.09x	$8.63 Million
Arovella Therapeutics Ltd (ALA)	$3.78 Million	-269.34%	0.45x	$42.76 Million
Anatara Lifesciences Ltd (ANR)	$1.36 Million	-185.61%	0.30x	$1.40 Million
Alterity Therapeutics Ltd (ATH)	$3.75 Million	-200.62%	0.23x	$108.75 Million
Amplia Therapeutics Ltd (ATX)	$6.07 Million	-40.21%	0.29x	$32.32 Million
Avecho Biotechnology Ltd (AVE)	$1.56 Million	-283.18%	3.56x	$32.81 Million

About Recce Pharmaceuticals Ltd

AU:RCE Australia Biotechnology

Market Cap

$71.40 Million

AU$100.90 Million AUD

Market Cap Rank

#20281 Global

#679 in Australia

Share Price

AU$0.33

Change (1 day)

+0.00%

52-Week Range

AU$0.27 - AU$0.71

All Time High

AU$1.68